FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137607488> ?p ?o ?g. }

• W2137607488 endingPage "295" @default.
• W2137607488 startingPage "285" @default.
• W2137607488 abstract "Objective To review the literature to determine the benefits of corticosteroids (CCSs) (oral, IM, IV, or inhaled) in the treatment of adult patients with acute asthma presenting at an acute-care setting. Search strategy A MEDLINE search was conducted using the following terms: (1) Asthma OR Wheez*, AND (2) Glucocorticoids OR Steroids, AND (3) Acute* OR Emerg. Other sources were the CURRENT CONTENTS database, review articles, reference sections of located studies, and a manual search of the top 15 journals for respiratory and emergency medicine. Selection criteria Patients were selected for the study by the following criteria: (1) English language; (2) adult patients with asthma whose acute exacerbations were the primary reason for assessment; (3) involvement in randomized, controlled trials conducted in an emergency care setting; (4) patients had participated in a study investigating a primary research question involving treatment with CCSs; and (5) outcomes based on results of pulmonary function tests and on hospital admission rates. Results At the 3-h assessment, only high doses of inhaled CCSs significantly improved pulmonary function compared with placebo (effect size [ES], 0.56; 95% confidence interval [CI], 0.15 to 0.97). On the other hand, after receiving IV CCSs, patients required at least 6 to 24 h to show moderate but nonsignificant improvements of pulmonary function (6-h ES, 0.44 [95% CI, −0.01 to 0.89]; 12-h ES, 0.54[95% CI, −0.08 to 1.17]; and 24-h ES, 0.53 [95% CI, −0.39 to 1.45]). The data from the six studies that we used to pool information on admission rate outcome showed a 32% reduction in favor of the use of IV CCSs (relative risk [RR], 0.68 [95% CI, 0.47 to 0.99]; number needed to treat, 12.5 [95% CI, 7.1 to 50]). However, the pooled effect of the three high-quality studies showed no difference between groups (RR, 1.21; 95% CI, 0.67 to 2.18). Oral CCSs provided a similarly beneficial effect on pulmonary function when compared with parenteral administration (ES, −0.14; 95% CI, −0.82 to 0.31. Finally, the results showed a nonsignificant favorable trend toward improved outcome with medium or high doses of CCSs. Conclusions This evidence-based evaluation suggests that the administration of parenteral CCSs to the patient on arrival at the emergency department (ED) neither improves airflow obstruction nor reduces the need for hospitalization. Parenteral CCSs probably require> 6 to 24 h to begin to act. Comprehensible conclusions about admission rates in the ED setting are difficult to make. At the 3-h assessment, only high doses of inhaled CCSs (in one study) significantly improved pulmonary function compared with placebo. IV and oral CCSs appear to have equivalent effects, and there is a tendency toward improvement in pulmonary function with medium or high doses. To review the literature to determine the benefits of corticosteroids (CCSs) (oral, IM, IV, or inhaled) in the treatment of adult patients with acute asthma presenting at an acute-care setting. A MEDLINE search was conducted using the following terms: (1) Asthma OR Wheez*, AND (2) Glucocorticoids OR Steroids, AND (3) Acute* OR Emerg. Other sources were the CURRENT CONTENTS database, review articles, reference sections of located studies, and a manual search of the top 15 journals for respiratory and emergency medicine. Patients were selected for the study by the following criteria: (1) English language; (2) adult patients with asthma whose acute exacerbations were the primary reason for assessment; (3) involvement in randomized, controlled trials conducted in an emergency care setting; (4) patients had participated in a study investigating a primary research question involving treatment with CCSs; and (5) outcomes based on results of pulmonary function tests and on hospital admission rates. At the 3-h assessment, only high doses of inhaled CCSs significantly improved pulmonary function compared with placebo (effect size [ES], 0.56; 95% confidence interval [CI], 0.15 to 0.97). On the other hand, after receiving IV CCSs, patients required at least 6 to 24 h to show moderate but nonsignificant improvements of pulmonary function (6-h ES, 0.44 [95% CI, −0.01 to 0.89]; 12-h ES, 0.54[95% CI, −0.08 to 1.17]; and 24-h ES, 0.53 [95% CI, −0.39 to 1.45]). The data from the six studies that we used to pool information on admission rate outcome showed a 32% reduction in favor of the use of IV CCSs (relative risk [RR], 0.68 [95% CI, 0.47 to 0.99]; number needed to treat, 12.5 [95% CI, 7.1 to 50]). However, the pooled effect of the three high-quality studies showed no difference between groups (RR, 1.21; 95% CI, 0.67 to 2.18). Oral CCSs provided a similarly beneficial effect on pulmonary function when compared with parenteral administration (ES, −0.14; 95% CI, −0.82 to 0.31. Finally, the results showed a nonsignificant favorable trend toward improved outcome with medium or high doses of CCSs. This evidence-based evaluation suggests that the administration of parenteral CCSs to the patient on arrival at the emergency department (ED) neither improves airflow obstruction nor reduces the need for hospitalization. Parenteral CCSs probably require> 6 to 24 h to begin to act. Comprehensible conclusions about admission rates in the ED setting are difficult to make. At the 3-h assessment, only high doses of inhaled CCSs (in one study) significantly improved pulmonary function compared with placebo. IV and oral CCSs appear to have equivalent effects, and there is a tendency toward improvement in pulmonary function with medium or high doses." @default.
• W2137607488 created "2016-06-24" @default.
• W2137607488 creator A5021482183 @default.
• W2137607488 creator A5081329959 @default.
• W2137607488 date "1999-08-01" @default.
• W2137607488 modified "2023-10-17" @default.
• W2137607488 title "Corticosteroids in the Emergency Department Therapy of Acute Adult Asthma" @default.
• W2137607488 cites W1511349137 @default.
• W2137607488 cites W1575218092 @default.
• W2137607488 cites W1915889733 @default.
• W2137607488 cites W1966313993 @default.
• W2137607488 cites W1972958851 @default.
• W2137607488 cites W1973417040 @default.
• W2137607488 cites W1979800562 @default.
• W2137607488 cites W1982900907 @default.
• W2137607488 cites W1985075877 @default.
• W2137607488 cites W1986393811 @default.
• W2137607488 cites W1990377101 @default.
• W2137607488 cites W1993338953 @default.
• W2137607488 cites W1997619217 @default.
• W2137607488 cites W2013187735 @default.
• W2137607488 cites W2017401841 @default.
• W2137607488 cites W2021196422 @default.
• W2137607488 cites W2021472715 @default.
• W2137607488 cites W2022282092 @default.
• W2137607488 cites W2025889766 @default.
• W2137607488 cites W2027830585 @default.
• W2137607488 cites W2030223911 @default.
• W2137607488 cites W2057290660 @default.
• W2137607488 cites W2066815911 @default.
• W2137607488 cites W2072795507 @default.
• W2137607488 cites W2080093885 @default.
• W2137607488 cites W2082853632 @default.
• W2137607488 cites W2085113067 @default.
• W2137607488 cites W2088097771 @default.
• W2137607488 cites W2092170655 @default.
• W2137607488 cites W2103455322 @default.
• W2137607488 cites W2107328434 @default.
• W2137607488 cites W2129829737 @default.
• W2137607488 cites W2152721327 @default.
• W2137607488 cites W2157823046 @default.
• W2137607488 cites W2162453125 @default.
• W2137607488 cites W2168226052 @default.
• W2137607488 cites W2169160058 @default.
• W2137607488 cites W2395119536 @default.
• W2137607488 cites W2417675419 @default.
• W2137607488 cites W4231532714 @default.
• W2137607488 cites W4232475713 @default.
• W2137607488 cites W4233036048 @default.
• W2137607488 cites W4367337360 @default.
• W2137607488 doi "https://doi.org/10.1378/chest.116.2.285" @default.
• W2137607488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10453853" @default.
• W2137607488 hasPublicationYear "1999" @default.
• W2137607488 type Work @default.
• W2137607488 sameAs 2137607488 @default.
• W2137607488 citedByCount "100" @default.
• W2137607488 countsByYear W21376074882012 @default.
• W2137607488 countsByYear W21376074882013 @default.
• W2137607488 countsByYear W21376074882014 @default.
• W2137607488 countsByYear W21376074882016 @default.
• W2137607488 countsByYear W21376074882017 @default.
• W2137607488 countsByYear W21376074882020 @default.
• W2137607488 countsByYear W21376074882021 @default.
• W2137607488 countsByYear W21376074882022 @default.
• W2137607488 crossrefType "journal-article" @default.
• W2137607488 hasAuthorship W2137607488A5021482183 @default.
• W2137607488 hasAuthorship W2137607488A5081329959 @default.
• W2137607488 hasConcept C118552586 @default.
• W2137607488 hasConcept C126322002 @default.
• W2137607488 hasConcept C142724271 @default.
• W2137607488 hasConcept C160735492 @default.
• W2137607488 hasConcept C162324750 @default.
• W2137607488 hasConcept C168563851 @default.
• W2137607488 hasConcept C17744445 @default.
• W2137607488 hasConcept C194828623 @default.
• W2137607488 hasConcept C199539241 @default.
• W2137607488 hasConcept C204787440 @default.
• W2137607488 hasConcept C27081682 @default.
• W2137607488 hasConcept C2776042228 @default.
• W2137607488 hasConcept C2776178081 @default.
• W2137607488 hasConcept C2777714996 @default.
• W2137607488 hasConcept C2779163699 @default.
• W2137607488 hasConcept C2779473830 @default.
• W2137607488 hasConcept C2780724011 @default.
• W2137607488 hasConcept C2781385661 @default.
• W2137607488 hasConcept C44249647 @default.
• W2137607488 hasConcept C50522688 @default.
• W2137607488 hasConcept C71924100 @default.
• W2137607488 hasConcept C75603125 @default.
• W2137607488 hasConceptScore W2137607488C118552586 @default.
• W2137607488 hasConceptScore W2137607488C126322002 @default.
• W2137607488 hasConceptScore W2137607488C142724271 @default.
• W2137607488 hasConceptScore W2137607488C160735492 @default.
• W2137607488 hasConceptScore W2137607488C162324750 @default.
• W2137607488 hasConceptScore W2137607488C168563851 @default.
• W2137607488 hasConceptScore W2137607488C17744445 @default.
• W2137607488 hasConceptScore W2137607488C194828623 @default.
• W2137607488 hasConceptScore W2137607488C199539241 @default.

• next